表紙
市場調查報告書
商品編碼
1069654

KRAS抑制劑的全球市場,臨床試驗預測(2028年)

Global KRAS Inhibitors Market & Clinical Trials Forecast 2028

出版日期: | 出版商: KuicK Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

Lumakras進入市場以來,KRAS抑制劑的市場規模大幅擴大,2021年的全球銷售額達到約9,000萬美元。也推動今後在這個領域的進一步研究開發活動。KRAS抑制劑的開發平台非常混亂,由Adagrasib,JQ443,GDC-6036,BI 1823911,JNJ-74699157,MK-1084等幾個潛在候補構成。

本報告提供全球KRAS抑制劑市場相關調查,提供向市場概要,以及KRAS抑制劑的作用機制,癌症治療的作用,各地區趨勢,臨床試驗趨勢,及市場參與企業的競爭趨勢等資訊。

目錄

第1章 KRAS抑制劑的簡介

  • 概要
  • KRAS抑制劑的演進

第2章 KRAS抑制劑-作用機制

第3章 癌症治療的KRAS抑制劑所扮演的角色

第4章 肺癌為目標的KRAS抑制劑

  • KRAS抑制劑對肺癌的影響
  • 進行中的研究開發

第5章 胰臟癌的KRAS抑制劑

  • 胰臟癌的KRAS抑制劑所扮演的角色
  • KRAS抑制劑為目標的胰臟癌的最近的進步

第6章 大腸癌的KRAS抑制劑

  • 對大腸癌的KRAS抑制劑的可能性
  • 進行中的研究開發

第7章 其他的癌症用KRAS抑制劑

  • 血液癌症治療藥的KRAS抑制劑的可能性
  • 前列腺癌的KRAS抑制劑
  • 胃癌的KRAS抑制劑
  • 子宮內膜癌的KRAS阻礙
  • 腦瘤的KRAS抑制劑所扮演的角色

第8章 Lumakras-最初批准KRAS抑制劑

  • 概要與專利趨勢
  • 劑量與價格分析
  • 至2028年的銷售額分析與預測

第9章 全球KRAS抑制劑市場概要

  • 目前市場情境
  • 未來市場機會

第10章 KRAS抑制劑市場的各地區分析-基於藥物核准

  • 美國
  • 英國
  • 中國
  • 歐洲
  • 日本
  • 韓國
  • 加拿大

第11章 全球KRAS抑制劑的臨床試驗指標

  • 各國
  • 各相
  • 各企業
  • 各適應症
  • 各患者市場區隔

第12章 全球KRAS抑制劑的臨床實驗平台,各企業,各適應症,各相

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第三階段
  • 預註冊

第13章 上市完畢的KRAS抑制劑的臨床性洞察

第14章 全球KRAS抑制劑市場力學

  • KRAS抑制劑市場促進因素
  • KRAS抑制劑市場課題

第15章 競爭情形

  • Amgen
  • Mirati Therapeutics
  • Revolution Medicines
  • Boehringer Ingelheim
  • Merck
  • Moderna
  • Silenseed Ltd
  • Johnson & Johnson
  • Eli Lilly
  • Oblique Therapeutics
  • Cotinga Pharmaceuticals
  • Codiak Biosciences
  • Gilead
目錄

"Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights:

  • KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028
  • US To Dominate Global KRAS Inhibitors Market: >50% Market Share
  • Number of KRAS Inhibitors In Trials: > 45 Drugs
  • Number of Approved Drugs: 1 (Lumakras)
  • Lumakras Dosage, Sales, Patent & Price Insight
  • Solid Tumors Targeted Drugs Dominating The Clinical Trials
  • Global KRAS Inhibitors Market Trends & Dynamics
  • Global KRAS Inhibitors Market Future Opportunity Outlook

The advancement in the field of clinical research has led to identification of several oncogenes which are generally mutated in cancers. Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated oncogene in lung carcinomas, accounting for 25% of total incidence, with half of them being KRASG12C mutations. Therefore, suitable research and development activities were carried out by pharmaceutical companies to develop novel KRAS inhibitor. To date, Lumakras developed by Amgen is the only KRAS inhibitor which haven approved for the management of non-small cell lung cancer.

The approval of Lumakras for the treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer marks a milestone for cancer therapy. Apart from small molecule inhibitor approach, researchers are also utilizing several other novel mechanisms to directly target KRAS including vaccines, adoptive T cell therapy, PROTACs, and CRISPR/Cas9 are emerging. Amid these approaches, a few KRAS vaccines have entered initial phase of clinical trials. ELI-002 developed by Elicio Therapeutics is a structurally novel AMP vaccine targeting KRAS driven cancers. The company is currently enrolling patients in AMPLIFY-201, phase-I/II clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer and pancreatic ductal adenocarcinoma.

Since the entry of Lumakras in the market, the drug has shown high adoption rates in the market with global sales of about US$ 90 Million in 2021. The encouraging response of the novel drug has propelled the further research and development activities in this segment. The pipeline of KRAS inhibitor is highly crowded and consists of several potential candidates including Adagrasib, JQ443, GDC-6036, BI 1823911, JNJ-74699157, MK-1084, and others. Among them, Adagrasib is one of the most advanced KRAS inhibitor in phase-III clinical trial while the others are mainly present in phase-I/II clinical trial.

Although KRAS G12C inhibitors offer an important new therapeutic option for a subset of patients with cancers, clinical trial experience suggests that fewer than half of patients respond and responses can be short-lived. To mitigate these challenges, ongoing clinical trials of KRAS inhibitors are largely focused on the evaluating novel rational combinations based on positive preclinical results. For instance, Bridge Bio Pharma in collaboration with Amgen is evaluating the combination of BBP-398, SHP2 inhibitor in combination with Lumakras in patients with advanced solid tumors with the KRAS G12C mutations. In addition to this, Mirati Therapeutics also announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib with Sanofi's investigational SHP2 inhibitor SAR442720 (RMC-4630).

With advances in precision medicine, there is unmet need for biomarker testing as it informs the treatment options during the course of disease. For KRAS mutations, Qiagen in 2021 announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RCQ PCR kit (therascreen KRAS Kit) after it received US regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with Lumakras. The company has collaborated with Labcorp to market the diagnostic test in US.

As per report findings, it is estimated that global KRAS inhibitor market will surpass US$ 4.5 Billion by 2028 driven by growing demand of targeted therapies and high acceptance in cancer management. The report offers comprehensive insights of the pipeline therapeutics scenario and growth prospects across KRAS Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, commercial information of already available KRAS inhibitor, and sales forecast till 2028. The report also provides regional analysis of the KRAS inhibitor market in US, Europe, China, Japan, Canada, Brazil, and other promising region.

Table of Contents

1. Introduction to KRAS Inhibitors

  • 1.1. Overview
  • 1.2. Evolution of KRAS Inhibitors

2. KRAS Inhibitors - Mode of Action

3. Role of KRAS Inhibitors in Cancer Therapy

4. KRAS Inhibitors For Targeting Lung Cancer

  • 4.1. Impact of KRAS Inhibitors on Lung Cancer
  • 4.2. Ongoing Research & Development

5. KRAS Inhibitors in Pancreatic Cancer

  • 5.1. Role of KRAS Inhibitors in Pancreatic Cancer
  • 5.2. Recent Advancement in Pancreatic Cancer Targeting KRAS Inhibitors

6. KRAS Inhibitors for Colorectal Cancer

  • 6.1. Potential of KRAS Inhibitors Against Colorectal Cancer
  • 6.2. Ongoing Research & Development

7. KRAS inhibitors For Other Cancers

  • 7.1. Potential of KRAS Inhibitors as Hematological Cancer Therapeutics
  • 7.2. KRAS inhibitors in Prostate Cancer
  • 7.3. KRAS Inhibitors for Gastric Cancer
  • 7.4. KRAS Inhibition in Endometrium Cancer
  • 7.5. Role of KRAS Inhibitors in Brain Cancer

8. Lumakras - 1st Approved KRAS Inhibitor

  • 8.1. Overview & Patent Insight
  • 8.2. Dosage & Price Analysis
  • 8.3. Sales Analysis & Forecast Till 2028

9. Global KRAS Inhibitor Market Overview

  • 9.1. Current Market Scenario
  • 9.2. Future Market Opportunity

10. KRAS Inhibitor Market Regional Analysis - Based On Drug Approval

  • 10.1. US
  • 10.2. UK
  • 10.3. China
  • 10.4. Europe
  • 10.5. Japan
  • 10.6. South Korea
  • 10.7. Canada

11. Global KRAS Inhibitors Clinical Trials Indicators

  • 11.1. By Country
  • 11.2. By Phase
  • 11.3. By Company
  • 11.4. By Indication
  • 11.5. By Patient Segment

12. Global KRAS Inhibitors Clinical Pipeline By Company, Indication & Phase

  • 12.1. Research
  • 12.2. Preclinical
  • 12.3. Phase-I
  • 12.4. Phase-I/II
  • 12.5. Phase-III
  • 12.6. Preregistration

13. Marketed KRAS Inhibitors Clinical Insight

14. Global KRAS Inhibitors Market Dynamics

  • 14.1. Driving Factors for KRAS Inhibitor Market
  • 14.2. Challenges for KRAS Inhibitors Market

15. Competitive Landscape

  • 15.1. Amgen
  • 15.2. Mirati Therapeutics
  • 15.3. Revolution Medicines
  • 15.4. Boehringer Ingelheim
  • 15.5. Merck
  • 15.6. Moderna
  • 15.7. Silenseed Ltd
  • 15.8. Johnson & Johnson
  • 15.9. Eli Lilly
  • 15.10. Oblique Therapeutics
  • 15.11. Cotinga Pharmaceuticals
  • 15.12. Codiak Biosciences
  • 15.13. Gilead

List of Figures

  • Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
  • Figure 1-2: Historical Development of KRAS Inhibitors
  • Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer
  • Figure 2-2: Targeting Approaches of KRAS Inhibitors
  • Figure 2-3: Direct Targeting of Mutant KRAS
  • Figure 2-4: Targets for Modifying the KRAS Membrane Association
  • Figure 3-1: KRAS Mutational Frequency by Organs (%)
  • Figure 3-2: Roles of KRAS Inhibitors in Cancer Treatment
  • Figure 4-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
  • Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
  • Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
  • Figure 4-4: Investigational KRAS Inhibitors for Lung Cancer
  • Figure 4-5: Codebreak 200 Trial - Study Initiation & Expected Completion Year
  • Figure 4-6: Codebreak 105 Trial - Study Initiation & Expected Completion Year
  • Figure 4-7: Codebreak 101 Trial - Study Initiation & Expected Completion Year
  • Figure 4-8: Krystal 7 trial - Study Initiation & Expected Completion Year
  • Figure 4-9: Krystal 1 trial - Study Initiation & Expected Completion Year
  • Figure 4-10: Krystal 2 trial - Study Initiation & Expected Completion Year
  • Figure 4-11: BI-1701963 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 4-12: mRNA-5671 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 4-13: Mechanism of BI-2852 against Lung Cancer
  • Figure 5-1: Global - Newly Diagnosed Cases & Deaths related to Pancreatic Cancer, 2020
  • Figure 5-2: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 5-3: Role of KRAS Inhibitors in Pancreatic Cancer
  • Figure 5-4: Investigational KRAS Inhibitors for Pancreatic Cancer
  • Figure 5-5: siG12D LODER Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 5-6: iExosomes Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-7: KRAS mTCR PBL Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-1: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
  • Figure 6-2: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
  • Figure 6-3: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 6-4: Investigational KRAS Inhibitors for Colorectal Cancer
  • Figure 7-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 7-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 7-3: Frequency of KRAS Mutation in Hematological Cancer (%)
  • Figure 7-4: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
  • Figure 7-5: Global - Number of Newly Diagnosed Gastric Cancer Cases & Deaths, 2020
  • Figure 7-6: Global - Number of Newly Diagnosed Cases of Endometrial Cancer by Type, 2020
  • Figure 7-7: Global - Number of Deaths of Endometrium Cancer by Type, 2020
  • Figure 7-8: Global - Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
  • Figure 8-1: Lumakras - Approval Year by Region
  • Figure 8-2: US - Lumakras Patent Expiration Year
  • Figure 8-3: US - Lumakras FDA Approval & Patent Exclusivity Year
  • Figure 8-4: US - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (US$), March'2022
  • Figure 8-5: UK - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (GBP/US$), March'2022
  • Figure 8-6: US - Monthly & Annual Treatment Cost with Lumakras (US$), March'2022
  • Figure 8-7: Lumakras - Recommended Initial & Reduced Dose (mg/day)
  • Figure 8-8: Global - Lumakras/Lumykras Annual Sales by Region (US$ Million), 2021
  • Figure 8-9: Global - Lumakras/Lumykras Annual Sales by Region (%), 2021
  • Figure 8-10: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2-Q4'2021
  • Figure 8-11: US - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2-Q4'2021
  • Figure 8-12: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), Q3 & Q4'2021
  • Figure 8-13: Global - Lumakras Sales Forecast (US$ Million), 2022 - 2028
  • Figure 8-14: US - Lumakras Sales Forecast (US$ Million), 2022 - 2028
  • Figure 9-1: Global - Cancer Incidences & Deaths (Million), 2020
  • Figure 9-2: KRAS Inhibitor Market Size by Region (US$ Million), 2021
  • Figure 9-3: KRAS Inhibitor Market Size by Region (%), 2021
  • Figure 9-4: Global - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 9-5: KRAS Inhibitor Market Size by Product (%), 2028
  • Figure 10-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-2: US vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
  • Figure 10-3: US vs. ROW - KRAS Inhibitor Market Size (%), 2021
  • Figure 10-4: US - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-5: UK - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-6: UK vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
  • Figure 10-7: UK vs. ROW - KRAS Inhibitor Market Size (%), 2021
  • Figure 10-8: UK - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-9: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-10: China - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-11: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-12: Europe - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-13: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-14: Japan - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-15: South Korea - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-16: South Korea - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 10-17: Canada - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 10-18: Canada vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2021
  • Figure 10-19: Canada vs. ROW - KRAS Inhibitor Market Size (%), 2021
  • Figure 10-20: Canada - KRAS Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 11-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2022 -2028
  • Figure 11-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2022 -2028
  • Figure 11-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2022 -2028
  • Figure 11- 4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2022 -2028
  • Figure 11-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2022 -2028
  • Figure 14-1: Drivers for KRAS Inhibitor Market
  • Figure 14-2: Challenges for KRAS Inhibitor Market
  • Figure 14-3: Global - Estimated Monthly Treatment Cost of AMG 150 v/s Other Cell Signal Targeting Therapeutics